At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
efatutazonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma
In Brief
A Phase 2 clinical trial evaluating efatutazone for Liposarcoma. Completed, enrolled 15 participants across 127 sites.
Detailed Summary
This phase II trial studies how well efatutazone dihydrochloride works in treating patients with previously treated myxoid liposarcoma that cannot be removed by surgery. Drugs used in chemotherapy, such as efatutazone dihydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiposarcoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Daiichi Sankyo
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartFeb 2015
Primary CompletionOct 2018
Study CompletionMay 2023
TodayJul 2026
First PostedSep 26, 2014
Enrollment StartFeb 11, 2015
Primary CompletionOct 4, 2018
Study CompletionMay 1, 2023
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 11.8 years ago
Interventions
efatutazonedrug
Given PO